Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China




Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless disease

TOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI^®” (brand name in China: “乐意保^®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, has been accepted by the National Medical Products Administration (NMPA) in China.

If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration in the hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive LEQEMBI treatment at home. The injection time for each autoinjector (250 mg injection) is approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion and nurse monitoring, while streamlining the overall AD treatment care pathway.

Eisai estimates that there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Eisai will distribute the product in China and will conduct information provision activities through specialized Medical Representatives.

*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.¹ Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.²  

Notes to Editors

1. About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保)
   Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been approved in 52 countries and is under regulatory review in 8 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in the U.S., China, the UK, and others, and applications have been filed in 4 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A rolling Supplemental Biologics License Application (sBLA) for initiation treatment was initiated under Fast Track status in September 2025, and completed in November 2025. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In December 2025, Lecanemab has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.

   Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

2. About the Collaboration between Eisai and Biogen for AD
   Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
3. About the Collaboration between Eisai and BioArctic for AD
   Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.
4. About Eisai Co., Ltd.
   Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

   In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

   For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

5. About Biogen
   Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

   The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

   Biogen Safe Harbor
   This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab (marketed as 乐意保 in China); potential regulatory discussions, submissions and approvals and the timing thereof including for LEQEMBI (lecanemab) subcutaneous autoinjector (SC-AI); the potential to streamline the Alzheimer’s disease treatment pathway; the anticipated benefits and potential of Biogen’s collaboration arrangements with Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

   These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

   These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

   Digital Media Disclosure
   From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References

1. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z
2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis




Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET –

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Conference Call and Webcast Details
Alumis’ conference call and webcast to discuss the topline data results from the Phase 3 ONWARD clinical program will begin Tuesday, January 6, 2026, at 8:00 a.m. ET. To access the live webcast please access this link or visit the “Events” page of the “Investors” section of the Alumis website at www.alumis.com. A replay of the webcast will be made available on the Company’s website following the call.

About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.

Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding the anticipated timing and availability of clinical data from the ONWARD Phase 3 clinical program. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

CONTACT: Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com

Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference




Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT

A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.

About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com   

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com 

Integra LifeSciences Holdings Corporation

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The Company granted non-qualified stock options to purchase 1,000,000 shares of common stock to its newly appointed Chief Commercial Officer, Arjun Prasad, and also granted non-qualified stock options to purchase 1,000,000 shares of common stock to its newly appointed Chief Medical Officer, Cynthia Sirard. The stock options have an exercise price of $5.17 per share, which is equal to the closing price of the Company’s common stock on January 2, 2026. The options have a 10-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remaining 75% vesting in 36 substantially equal monthly installments thereafter, subject to each respective employee’s continued service with the Company.

These inducement grants were approved by Compass Therapeutics Compensation Committee of the Board of Directors as a material inducement to employment. They were granted outside of the Company’s 2020 Stock Option and Incentive Plan and are subject to the Company’s 2025 Inducement Plan and the applicable award agreements.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development and commercialization as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com 

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com 
617-500-8099

Citrus Burn Examined (URGENT REPORT) The Science Behind the Orange Peel Trick for Metabolic Support




Citrus Burn Examined (URGENT REPORT) The Science Behind the Orange Peel Trick for Metabolic Support

New York City, Jan. 05, 2026 (GLOBE NEWSWIRE) —

January 5, 2026

Citrus Burn is a citrus-derived dietary supplement formulated to support metabolism, daily energy levels, and thermogenic activity through plant-based ingredients.

As interest in natural metabolism support supplements continues to increase, CitrusBurn has gained attention for its focus on citrus peel extracts, particularly compounds derived from Seville orange peel. These ingredients are often discussed online in relation to the so-called “orange peel trick” for metabolism support, a growing wellness trend centered on citrus-based metabolic efficiency.

Unlike stimulant-heavy fat burners, CitrusBurn is positioned as a metabolism support formula designed to complement balanced nutrition and healthy lifestyle habits. The formulation reflects a modern shift toward botanical-based supplements that emphasize metabolic balance, energy regulation, and long-term sustainability rather than aggressive short-term weight loss claims.

For those researching CitrusBurn ingredients, scientific background, or current offers, the official Citrus Burn website provides detailed resources to help support informed decision-making.

The Orange Peel Trick Explained: Separating Online Buzz From Scientific Context

What Is the Orange Peel Trick for Metabolism Support?

The term “orange peel trick” has become popular across wellness blogs, social media platforms, and supplement review websites. In most cases, it refers to the use of citrus peel–derived compounds, particularly from bitter or Seville oranges, to support metabolic activity, appetite awareness, and energy balance.

Unlike consuming whole oranges, citrus peels contain higher concentrations of specific bioactive compounds that are present only in small amounts in the fruit’s juice or pulp. These compounds have been studied for their potential interaction with metabolic receptors, enzymes involved in fat oxidation, and thermogenic signaling pathways.

It is important to clarify that the orange peel trick is not a medical protocol or a guaranteed weight-loss method. Instead, it is a consumer-friendly term describing increased interest in citrus peel–based nutritional support for metabolism.

Orange Peel Method for Weight Support: Why Citrus Peels Are Different

Citrus peels differ significantly from citrus flesh in their phytochemical composition. The outer rind contains flavonoids, alkaloids, and aromatic plant compounds that serve protective functions for the fruit. In nutritional research, these same compounds are being evaluated for their antioxidant properties and potential roles in metabolic regulation.

Seville orange peel, in particular, has been examined for compounds linked to thermogenic activity and energy expenditure. Rather than acting as harsh stimulants, these compounds are associated with metabolic signaling pathways related to fat utilization and energy efficiency.

CitrusBurn incorporates citrus peel extracts as part of a broader botanical blend designed to support metabolism without relying on excessive caffeine or synthetic stimulants. This is a key distinction often noted when comparing citrus-based metabolism supplements to traditional stimulant-driven fat burners. Find out more about the Orange Peel Trick here and how it works exactly!

Why the Orange Peel Approach Appeals to Modern Consumers

The growing popularity of citrus peel–based supplements can be attributed to several factors:

• Plant-based ingredients: Citrus peels align with clean-label and natural wellness preferences
• Lower stimulant perception: Often viewed as gentler than high-caffeine metabolism products
• Metabolic efficiency focus: Emphasizes balance and sustainability over forced calorie burn
• Easy daily use: Typically integrates into everyday routines without strict timing rules

As awareness around long-term metabolic health continues to grow, many consumers are turning toward metabolism support supplements that prioritize consistency, balance, and sustainable results rather than short-term intensity.

Introducing Citrus Burn: A Citrus-Based Metabolism Support Supplement

CitrusBurn is a citrus-based metabolism support supplement formulated to help support thermogenesis, energy utilization, and appetite awareness through a blend of citrus-derived botanicals and complementary plant-based nutrients.

As consumer interest in natural metabolic health continues to grow, Citrus Burn has positioned itself as a metabolism-focused dietary supplement rather than a rapid weight-loss product. According to publicly available product information, the formula is designed to work alongside balanced nutrition and lifestyle habits, supporting metabolic efficiency instead of promoting extreme or short-term results.

Rather than relying on a single active compound, CitrusBurn uses a multi-ingredient formulation strategy commonly found in modern nutraceuticals. This approach reflects the understanding that metabolic function involves multiple biological pathways, including energy production, fat utilization, and glucose regulation.

CitrusBurn is primarily marketed toward adults seeking ongoing metabolic support, particularly individuals who feel their metabolism has slowed with age despite maintaining consistent dietary and physical activity routines.

How CitrusBurn Uses Ingredient Synergy for Metabolic Support

Ingredient synergy is a formulation concept in which multiple complementary compounds are combined to support broader physiological processes more effectively than isolated ingredients. In metabolism support supplements, this often involves blending ingredients associated with thermogenic activity, energy metabolism, and blood sugar balance.

Citrus Burn emphasizes citrus peel extracts alongside botanicals commonly linked to metabolic health and energy regulation. While many of the individual ingredients included in CitrusBurn have research supporting their standalone use, the finished formulation itself is positioned as a general wellness supplement rather than a clinically validated treatment.

This positioning aligns with dietary supplement regulations, which require products to focus on supporting normal bodily functions and overall wellness rather than making disease-related or therapeutic claims.

CitrusBurn Ingredients: What Is Included in the Formula?

CitrusBurn is formulated using a blend of citrus-derived botanicals and plant-based metabolic cofactors selected to support thermogenesis, appetite awareness, and efficient energy metabolism.

Instead of relying on high doses of caffeine or synthetic stimulants, the formula focuses on ingredient synergy, allowing multiple metabolic pathways involved in fat utilization and energy production to function together in a more balanced manner.

Seville Orange Peel (p-Synephrine)

Seville orange peel, sourced from bitter orange, contains p-synephrine, a compound that has been studied for its role in supporting thermogenic activity and metabolic function. Unlike traditional stimulants, p-synephrine is often associated with promoting fat oxidation and energy expenditure without producing strong stimulant effects such as jitteriness or energy crashes.

Spanish Red Apple Vinegar

Spanish red apple vinegar is commonly included in metabolism support formulas for its potential role in supporting appetite awareness and digestive comfort. This ingredient is often associated with helping users feel fuller after meals while also contributing to more stable blood sugar responses, which can support consistent energy levels throughout the day.

Green Tea Extract

Green tea extract is a well-researched botanical that contains catechins known for their antioxidant properties and association with fat metabolism. In metabolic supplements, green tea extract is commonly included to support fat oxidation, contribute to natural energy production, and provide cellular antioxidant support.

Himalayan Mountain Ginger

Himalayan mountain ginger has a long history of traditional use in digestive and metabolic support. In modern formulations, it is often included for its potential role in supporting digestive efficiency, managing cravings, and promoting overall metabolic balance.

Berberine and Korean Red Ginseng

Berberine and Korean red ginseng are included in CitrusBurn for their association with metabolic and hormonal balance. Berberine is commonly studied for its potential role in supporting glucose metabolism and insulin sensitivity, while Korean red ginseng is often linked to improved vitality, energy support, and stress resilience.

Note: Research generally supports individual ingredients rather than the finished Citrus Burn formulation. Individual results may vary.

Potential Benefits Commonly Associated With CitrusBurn

Citrus Burn is promoted as a daily metabolism support supplement designed to work in harmony with the body’s natural fat-burning and energy-production processes.

While individual outcomes can vary, citrus-based metabolic supplements like CitrusBurn are commonly associated with several potential benefits.

CitrusBurn is designed to support natural thermogenic activity, helping the body convert stored calories into usable energy more efficiently. Certain ingredients in the formula may also support appetite awareness, which can help reduce unnecessary snacking and manage cravings throughout the day.

Unlike stimulant-heavy products, Citrus Burn aims to promote clean, sustained energy, supporting steady energy levels, reduced crashes, and improved daily focus. Additionally, metabolic cofactors such as berberine and vinegar extracts are often associated with supporting balanced blood sugar levels and more consistent energy output.

CitrusBurn is intended to complement healthy nutrition and regular physical activity, making it suitable for individuals pursuing lifestyle-based weight and metabolic goals rather than quick-fix solutions.

CitrusBurn Pricing: Package Options and Cost Breakdown

CitrusBurn pricing is structured around multi-bottle packages designed to support consistent, long-term metabolic use. This tiered pricing approach is common among metabolism support supplements and allows customers to choose a package based on their usage goals and budget.

CitrusBurn Available Packages and Prices

• 6-Bottle Package (180-Day Supply)
  • Approximate cost: $49 per bottle
  • Lowest price per unit
  • Frequently includes free shipping
  • Most commonly selected option for long-term metabolic support
• 3-Bottle Package (90-Day Supply)
  • Approximate cost: $69 per bottle
  • Mid-range pricing option
  • Popular choice for first-time CitrusBurn users
• 2-Bottle Package (60-Day Supply)
  • Approximate cost: $79 per bottle
  • Entry-level package
  • Suitable for short-term evaluation before committing to a larger supply

Pricing and promotional discounts may vary depending on availability, seasonal offers, and demand. Multi-bottle packages are generally recommended for individuals seeking ongoing metabolism support.

Where to Buy CitrusBurn Safely

CitrusBurn is primarily available for purchase through the official CitrusBurn website. Buying directly from the source helps ensure product authenticity, proper storage conditions, and access to customer guarantees.

Recommended Purchasing Guidelines

To avoid counterfeit or expired products, consumers are typically encouraged to:

• Buy CitrusBurn only from the official website
• Avoid third-party marketplaces or unauthorized sellers
• Review current promotions, refund terms, and shipping details before ordering

CitrusBurn Shipping and Money-Back Guarantee

Most official Citrus Burn orders include secure checkout, tracked shipping, and access to a money-back guarantee that may extend up to 180 days. Purchasing directly from the official source helps ensure eligibility for customer support, refund policies, and verified product quality.

Below is a more SEO-optimized version of your content.
I’ve strengthened keyword targeting, heading hierarchy, semantic depth, and search intent alignment while keeping the meaning, tone, and compliance intact.

Primary SEO focus keywords integrated naturally:

• Citrus-based metabolism supplements
• Citrus-derived nutrients
• Orange peel trick
• Thermogenesis support
• Metabolic efficiency
• Natural thermogenic supplements
• CitrusBurn metabolism support

Understanding the Rising Interest in Citrus-Based Metabolism Supplements

Citrus-based metabolism supplements have gained significant attention in recent years as consumers seek natural, plant-derived options to support metabolic health, energy balance, and thermogenic activity. This growing interest reflects both advances in ingredient research and shifting consumer preferences toward sustainable, stimulant-free metabolic support.

Why Citrus-Derived Nutrients Are Gaining Attention in Metabolic Health

Over the past decade, citrus-derived nutrients have become an increasingly studied focus within nutritional science and the dietary supplement industry. Citrus fruits, and especially their peels, contain naturally occurring bioactive compounds such as flavonoids, alkaloids, and polyphenols. These compounds are being examined for their roles in metabolic signaling, antioxidant defense, and cellular energy regulation.

Citrus peels, in particular, have attracted attention because they contain higher concentrations of certain compounds that are not present in the same amounts within the fruit pulp. Research has explored these compounds in relation to fat oxidation, glucose metabolism, and appetite-related signaling pathways. This expanding body of ingredient-level research has contributed to online discussions commonly referred to as the “orange peel trick” or “orange peel hack” for metabolism and weight management.

While these phrases are widely used in consumer-focused content, nutrition researchers and supplement formulators emphasize that citrus-derived compounds should be evaluated within a broader metabolic framework. No single ingredient is viewed as a standalone solution, and metabolic health is influenced by multiple interconnected biological processes.

Growing Consumer Demand for Natural Thermogenic Support

Global demand for metabolism support supplements has accelerated, particularly among adults over the age of 35 who experience natural metabolic changes related to hormonal shifts, reduced thermogenesis, and altered energy expenditure. As awareness grows, many consumers are actively seeking alternatives to traditional stimulant-heavy fat burners, which are often associated with jitteriness, sleep disruption, and inconsistent energy levels.

Citrus-based thermogenic supplements have emerged as a category positioned between functional nutrition and conventional fat-burning products. These formulas typically emphasize plant-based ingredients, moderate metabolic activation, and compatibility with daily routines. CitrusBurn aligns with this positioning by combining citrus peel extracts with other botanicals commonly associated with metabolic support and energy balance.

Industry analysts note that the appeal of citrus-based metabolism supplements is driven not only by ingredient research but also by consumer preferences for clean-label formulations, non-habit-forming products, and solutions that support gradual, sustainable metabolic outcomes rather than rapid or extreme weight fluctuations.

The Science Behind Thermogenesis and Metabolic Efficiency

What Is Thermogenesis and Why It Declines With Age

Thermogenesis refers to the body’s natural process of producing heat through calorie expenditure. This process plays a key role in regulating body temperature, supporting digestion, and determining how efficiently the body converts stored energy into usable fuel. A significant portion of daily calorie burn occurs through thermogenic activity rather than physical movement alone.

Scientific research suggests that thermogenic efficiency tends to decline with age, particularly after the mid-30s. Factors contributing to this decline may include reduced mitochondrial function, hormonal changes, shifts in insulin sensitivity, and alterations in nervous system signaling. As thermogenesis becomes less efficient, maintaining body composition can become more challenging even when diet and activity habits remain unchanged.

These age-related changes have prompted researchers to examine dietary compounds and botanical extracts that may help support thermogenic pathways without overstimulating the nervous system.

Thermogenic Resistance and Its Impact on Weight Management

Thermogenic resistance is a term increasingly used to describe reduced responsiveness to signals that initiate fat oxidation and calorie burning. In practical terms, this means the body may store energy more easily while becoming less efficient at accessing stored fat for fuel.

Although research in this area is ongoing, metabolic experts generally agree that supporting thermogenesis requires a multifactor approach that includes nutrition, physical activity, sleep quality, and hormonal balance. Supplements such as CitrusBurn are positioned as supportive tools within this broader lifestyle framework rather than as primary drivers of metabolic change.

By focusing on citrus-derived compounds associated with metabolic signaling, Citrus Burn is marketed as a formula intended to complement healthy habits rather than replace them.

Metabolism, Energy Production, and Fat Oxidation Explained

Metabolism refers to the complex network of biochemical processes responsible for converting food into energy, maintaining cellular structure, and supporting overall physiological balance. Fat oxidation is one component of metabolism and involves breaking down stored lipids into energy molecules that the body can use.

Certain plant-based compounds have been studied for their influence on enzymes and receptors involved in these processes. Citrus-derived flavonoids, alkaloids, and polyphenols have been examined for their potential roles in energy expenditure and metabolic signaling, particularly when used alongside other supportive nutrients.

CitrusBurn’s formulation reflects this ingredient synergy approach, emphasizing balanced metabolic support rather than isolated stimulation. This strategy aligns with evolving scientific perspectives that favor sustainable metabolic activation over aggressive, short-term calorie-burning methods.

Key Citrus-Derived Compounds and Their Roles in Metabolic Support

Citrus-derived compounds have become a major focus in the development of citrus-based metabolism supplements due to their association with thermogenesis, energy balance, and metabolic efficiency. These naturally occurring plant compounds are commonly studied for their ability to support calorie utilization without overstimulating the nervous system.

Citrus Peel Compounds and Thermogenic Signaling

Citrus peels contain naturally occurring alkaloids and flavonoids that have been studied for their interaction with adrenergic receptors involved in energy expenditure. These interactions may help support mild thermogenic activity, which can contribute to increased calorie burning when combined with regular physical activity and balanced nutrition.

Unlike high-dose synthetic stimulants, citrus-derived thermogenic compounds are often described as supporting metabolic alertness rather than triggering sharp spikes in nervous system stimulation. This more moderate effect profile has contributed to their widespread use in daily metabolism support supplements such as CitrusBurn.

Citrus Flavonoids and Antioxidant Support for Metabolic Health

Flavonoids found in citrus peels, including hesperidin and related polyphenols, are widely recognized for their antioxidant properties. Antioxidants play an important role in protecting cells from oxidative stress, a process closely associated with metabolic aging and reduced cellular efficiency.

By supporting antioxidant defenses, citrus-derived flavonoids may help maintain healthier metabolic function over time. This benefit is frequently discussed in the context of long-term metabolic wellness rather than short-term or rapid weight loss, aligning with the positioning of citrus-based metabolism supplements.

Energy Balance, Appetite Awareness, and Metabolic Regulation

Beyond thermogenic pathways, certain citrus-derived compounds have been examined for their potential influence on appetite signaling and blood sugar regulation. Stable energy levels and reduced fluctuations in hunger may help support healthier eating behaviors and more consistent dietary patterns.

CitrusBurn’s formulation approach emphasizes metabolic awareness rather than artificial appetite suppression. This positioning aligns with growing consumer demand for natural metabolism support solutions that work alongside lifestyle habits instead of overriding normal physiological signals.

Citrus Burn Ingredient Framework: A Research-Based Perspective

Ingredient-Level Research vs Finished Product Claims

Within the dietary supplement industry, scientific evidence is most commonly available at the individual ingredient level rather than for finished formulations. CitrusBurn follows this standard approach by incorporating botanicals and micronutrients that have been individually studied for roles related to metabolism, thermogenesis, energy regulation, and appetite awareness.

While CitrusBurn as a completed supplement has not been publicly linked to large-scale independent clinical trials, its formulation reflects ingredients that appear frequently in metabolic and thermogenic research literature. Understanding this distinction is essential for consumers evaluating metabolism support supplements responsibly.

Seville Orange Peel (Citrus aurantium) and Metabolic Support

Seville orange peel extract is one of the most widely discussed citrus-derived ingredients in metabolism-focused supplements. Research on Citrus aurantium has examined compounds such as p-synephrine, which may support metabolic rate through interactions with adrenergic receptor pathways involved in fat oxidation and energy expenditure.

Unlike ephedrine-based stimulants, p-synephrine is often described in scientific literature as having a milder cardiovascular impact when used responsibly and at appropriate doses. This characteristic has contributed to its inclusion in citrus-based thermogenic supplements designed for regular use.

Individual responses may vary depending on health status, stimulant sensitivity, and total caffeine intake from other sources.

Green Tea Extract and Fat Oxidation Support

Green tea extract is among the most extensively researched botanicals in metabolic health studies. Its catechins, particularly epigallocatechin gallate (EGCG), have been examined for their potential role in supporting fat oxidation and increasing energy expenditure.

Green tea extract is commonly included in metabolism supplements because it offers both antioxidant support and mild thermogenic activity. When combined with citrus-derived compounds, it may help support calorie utilization during physical activity and daily movement.

CitrusBurn includes green tea–derived compounds as part of a broader metabolic support framework rather than positioning them as a standalone fat-burning solution.

Botanical Cofactors and Cellular Energy Regulation

In addition to citrus peel and green tea extracts, CitrusBurn formulations typically include botanical cofactors associated with energy metabolism and nutrient utilization. These ingredients are selected to complement thermogenic compounds rather than amplify stimulant effects.

Such cofactors may help support mitochondrial function, carbohydrate metabolism, and cellular energy production. This formulation philosophy reflects modern supplement trends that prioritize metabolic efficiency, balance, and sustainability over aggressive stimulation.

How CitrusBurn Differs From Traditional Fat Burners

Citrus Burn is often compared to traditional fat burners due to its citrus-based formulation and non-stimulant-forward positioning. Understanding how CitrusBurn differs from conventional fat-burning supplements can help consumers evaluate whether citrus-based metabolism support aligns with their goals and tolerance preferences.

Stimulant-Heavy Fat Burners vs Citrus-Based Metabolism Support

Many traditional fat burners rely on high doses of caffeine, synthetic stimulants, or aggressive thermogenic compounds designed to rapidly increase heart rate and central nervous system activity. While some consumers seek this immediate surge of energy, others report side effects such as jitteriness, energy crashes, sleep disruption, or poor long-term tolerance.

CitrusBurn is positioned as a citrus-based metabolism support supplement that emphasizes smoother energy and daily usability rather than intense stimulation. This contrast is frequently highlighted in comparisons between citrus-derived metabolism supplements and conventional stimulant-heavy fat burners.

“Clean Energy” Support vs Jitter-Driven Stimulation

A commonly discussed concept in CitrusBurn reviews and consumer feedback is the idea of “clean energy.” This term is often used to describe energy support that feels steady and manageable, without the nervousness, anxiety, or abrupt energy drops associated with high-stimulant products.

Citrus-derived compounds and botanical extracts are frequently framed as supporting metabolic alertness and energy balance without overwhelming the nervous system. While individual responses vary, this positioning reflects broader wellness trends favoring sustainable energy over short-lived stimulation.

Appetite Awareness Compared to Appetite Suppression

Traditional fat burners often aim to suppress appetite through aggressive mechanisms, which may not support long-term dietary adherence. In contrast, citrus-based metabolism supplements are commonly marketed as supporting appetite awareness and natural satiety signals.

CitrusBurn’s formulation messaging aligns with this approach by emphasizing metabolic support alongside mindful eating habits, rather than presenting the supplement as a substitute for proper nutrition or a tool for extreme calorie restriction.

Safety, Tolerance, and Responsible Supplement Use

Who Typically Uses Citrus-Based Metabolism Supplements

CitrusBurn is generally marketed toward adults seeking metabolic support, particularly individuals who feel their metabolism has slowed with age. This includes people who maintain consistent diet and exercise routines but are looking for additional nutritional support to complement their lifestyle.

As with all dietary supplements, CitrusBurn is not intended to diagnose, treat, cure, or prevent disease. Individuals with medical conditions, stimulant sensitivities, or those taking prescription medications are encouraged to consult a healthcare professional before use.

Potential Interactions and Sensitivity Considerations

Some citrus-derived compounds may interact with medications, especially those processed through liver enzyme pathways. Individuals sensitive to stimulants should also consider their total daily intake of caffeine and related compounds from all dietary sources.

Responsible use includes following label directions, avoiding excessive stacking with other stimulant-containing supplements, and monitoring individual response over time.

Manufacturing Standards and Product Quality Considerations

CitrusBurn products are typically manufactured in facilities that comply with standard dietary supplement regulations, including Good Manufacturing Practices (GMP). These standards address ingredient sourcing, purity, and manufacturing consistency.

Although regulatory compliance does not equate to clinical effectiveness, it provides a baseline level of quality assurance for consumers navigating the metabolism supplement market.

Growing Consumer Demand for Citrus-Based Metabolism Supplements

Why Citrus-Derived Formulas Are Increasingly Popular

Over the past decade, consumer preferences in the supplement industry have shifted toward plant-based, clean-label, and naturally sourced products. Citrus-based metabolism supplements like CitrusBurn have emerged within this trend, benefiting from long-standing associations between citrus ingredients and wellness, digestion, and vitality.

Citrus flavors and botanical extracts are often perceived as fresher and more approachable than synthetic stimulant blends. This perception plays a meaningful role in consumer adoption, especially among individuals seeking metabolism support without aggressive stimulation.

Metabolism Support Demand After Age 35

Age-related metabolic slowdown is one of the most common reasons consumers explore metabolism supplements. Research and consumer surveys consistently show that adults over 35 often experience increased difficulty managing energy levels, appetite regulation, and body composition, even when diet and exercise habits remain consistent.

CitrusBurn and similar citrus-based metabolism supplements are frequently positioned toward this demographic, offering a formulation narrative focused on supporting natural metabolic pathways rather than promoting rapid or extreme weight loss.

This audience often prioritizes sustainable energy, digestive comfort, ingredient tolerance, and products that integrate easily into daily routines.

Clean-Label Preferences and Ingredient Transparency

Ingredient transparency has become a major decision factor for supplement buyers. Many consumers now review ingredient lists, sourcing information, and manufacturing practices before making a purchase.

CitrusBurn’s emphasis on recognizable botanical ingredients aligns with this clean-label trend. Citrus-derived compounds, green tea extracts, and botanical cofactors are generally more familiar to consumers than synthetic stimulants, contributing to higher perceived trust and confidence.

Conclusion: Should You Buy CitrusBurn?

Citrus Burn operates within the growing natural metabolism and weight-management supplement category, leveraging consumer interest in citrus-derived botanicals and functional nutrition.

While CitrusBurn is not a medical treatment or guaranteed solution, its formulation reflects current market preferences that favor plant-based ingredients, metabolic pathway support, and clean-label positioning.

As consumer awareness continues to evolve, citrus-based metabolism supplements like CitrusBurn are likely to remain central to discussions around metabolic health, lifestyle wellness, and nutraceutical innovation.

Final Note on Citrus Burn

Like all dietary supplements, CitrusBurn is best viewed as part of a broader wellness strategy that includes balanced nutrition, regular physical activity, and informed health decisions. For official product details, guarantees, and current availability, consumers are encouraged to visit the official CitrusBurn website.

Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. CitrusBurn is a dietary supplement and is not designed to diagnose, treat, cure, or prevent any disease. Individual results may vary depending on health status, lifestyle, and personal factors. Always consult a qualified healthcare professional before starting any new supplement, especially if you are pregnant, nursing, have a medical condition, or are taking prescription medications. Do not exceed recommended dosages. This content should not replace professional medical guidance, nutritional counseling, or personalized health advice from a licensed practitioner.

Project name: CitrusBurn

• Phone
  + 1 (800) 390-6035 (24/7)
• Email support@citrusburn.com.
• Advertise with us: Info@allprsolution.com

Citrus Burn Examined (URGENT REPORT) The Science Behind the Orange Peel Trick for Metabolic Support




Citrus Burn Examined (URGENT REPORT) The Science Behind the Orange Peel Trick for Metabolic Support

New York City, Jan. 05, 2026 (GLOBE NEWSWIRE) —

January 5, 2026

Citrus Burn is a citrus-derived dietary supplement formulated to support metabolism, daily energy levels, and thermogenic activity through plant-based ingredients.

As interest in natural metabolism support supplements continues to increase, CitrusBurn has gained attention for its focus on citrus peel extracts, particularly compounds derived from Seville orange peel. These ingredients are often discussed online in relation to the so-called “orange peel trick” for metabolism support, a growing wellness trend centered on citrus-based metabolic efficiency.

Unlike stimulant-heavy fat burners, CitrusBurn is positioned as a metabolism support formula designed to complement balanced nutrition and healthy lifestyle habits. The formulation reflects a modern shift toward botanical-based supplements that emphasize metabolic balance, energy regulation, and long-term sustainability rather than aggressive short-term weight loss claims.

For those researching CitrusBurn ingredients, scientific background, or current offers, the official Citrus Burn website provides detailed resources to help support informed decision-making.

The Orange Peel Trick Explained: Separating Online Buzz From Scientific Context

What Is the Orange Peel Trick for Metabolism Support?

The term “orange peel trick” has become popular across wellness blogs, social media platforms, and supplement review websites. In most cases, it refers to the use of citrus peel–derived compounds, particularly from bitter or Seville oranges, to support metabolic activity, appetite awareness, and energy balance.

Unlike consuming whole oranges, citrus peels contain higher concentrations of specific bioactive compounds that are present only in small amounts in the fruit’s juice or pulp. These compounds have been studied for their potential interaction with metabolic receptors, enzymes involved in fat oxidation, and thermogenic signaling pathways.

It is important to clarify that the orange peel trick is not a medical protocol or a guaranteed weight-loss method. Instead, it is a consumer-friendly term describing increased interest in citrus peel–based nutritional support for metabolism.

Orange Peel Method for Weight Support: Why Citrus Peels Are Different

Citrus peels differ significantly from citrus flesh in their phytochemical composition. The outer rind contains flavonoids, alkaloids, and aromatic plant compounds that serve protective functions for the fruit. In nutritional research, these same compounds are being evaluated for their antioxidant properties and potential roles in metabolic regulation.

Seville orange peel, in particular, has been examined for compounds linked to thermogenic activity and energy expenditure. Rather than acting as harsh stimulants, these compounds are associated with metabolic signaling pathways related to fat utilization and energy efficiency.

CitrusBurn incorporates citrus peel extracts as part of a broader botanical blend designed to support metabolism without relying on excessive caffeine or synthetic stimulants. This is a key distinction often noted when comparing citrus-based metabolism supplements to traditional stimulant-driven fat burners. Find out more about the Orange Peel Trick here and how it works exactly!

Why the Orange Peel Approach Appeals to Modern Consumers

The growing popularity of citrus peel–based supplements can be attributed to several factors:

• Plant-based ingredients: Citrus peels align with clean-label and natural wellness preferences
• Lower stimulant perception: Often viewed as gentler than high-caffeine metabolism products
• Metabolic efficiency focus: Emphasizes balance and sustainability over forced calorie burn
• Easy daily use: Typically integrates into everyday routines without strict timing rules

As awareness around long-term metabolic health continues to grow, many consumers are turning toward metabolism support supplements that prioritize consistency, balance, and sustainable results rather than short-term intensity.

Introducing Citrus Burn: A Citrus-Based Metabolism Support Supplement

CitrusBurn is a citrus-based metabolism support supplement formulated to help support thermogenesis, energy utilization, and appetite awareness through a blend of citrus-derived botanicals and complementary plant-based nutrients.

As consumer interest in natural metabolic health continues to grow, Citrus Burn has positioned itself as a metabolism-focused dietary supplement rather than a rapid weight-loss product. According to publicly available product information, the formula is designed to work alongside balanced nutrition and lifestyle habits, supporting metabolic efficiency instead of promoting extreme or short-term results.

Rather than relying on a single active compound, CitrusBurn uses a multi-ingredient formulation strategy commonly found in modern nutraceuticals. This approach reflects the understanding that metabolic function involves multiple biological pathways, including energy production, fat utilization, and glucose regulation.

CitrusBurn is primarily marketed toward adults seeking ongoing metabolic support, particularly individuals who feel their metabolism has slowed with age despite maintaining consistent dietary and physical activity routines.

How CitrusBurn Uses Ingredient Synergy for Metabolic Support

Ingredient synergy is a formulation concept in which multiple complementary compounds are combined to support broader physiological processes more effectively than isolated ingredients. In metabolism support supplements, this often involves blending ingredients associated with thermogenic activity, energy metabolism, and blood sugar balance.

Citrus Burn emphasizes citrus peel extracts alongside botanicals commonly linked to metabolic health and energy regulation. While many of the individual ingredients included in CitrusBurn have research supporting their standalone use, the finished formulation itself is positioned as a general wellness supplement rather than a clinically validated treatment.

This positioning aligns with dietary supplement regulations, which require products to focus on supporting normal bodily functions and overall wellness rather than making disease-related or therapeutic claims.

CitrusBurn Ingredients: What Is Included in the Formula?

CitrusBurn is formulated using a blend of citrus-derived botanicals and plant-based metabolic cofactors selected to support thermogenesis, appetite awareness, and efficient energy metabolism.

Instead of relying on high doses of caffeine or synthetic stimulants, the formula focuses on ingredient synergy, allowing multiple metabolic pathways involved in fat utilization and energy production to function together in a more balanced manner.

Seville Orange Peel (p-Synephrine)

Seville orange peel, sourced from bitter orange, contains p-synephrine, a compound that has been studied for its role in supporting thermogenic activity and metabolic function. Unlike traditional stimulants, p-synephrine is often associated with promoting fat oxidation and energy expenditure without producing strong stimulant effects such as jitteriness or energy crashes.

Spanish Red Apple Vinegar

Spanish red apple vinegar is commonly included in metabolism support formulas for its potential role in supporting appetite awareness and digestive comfort. This ingredient is often associated with helping users feel fuller after meals while also contributing to more stable blood sugar responses, which can support consistent energy levels throughout the day.

Green Tea Extract

Green tea extract is a well-researched botanical that contains catechins known for their antioxidant properties and association with fat metabolism. In metabolic supplements, green tea extract is commonly included to support fat oxidation, contribute to natural energy production, and provide cellular antioxidant support.

Himalayan Mountain Ginger

Himalayan mountain ginger has a long history of traditional use in digestive and metabolic support. In modern formulations, it is often included for its potential role in supporting digestive efficiency, managing cravings, and promoting overall metabolic balance.

Berberine and Korean Red Ginseng

Berberine and Korean red ginseng are included in CitrusBurn for their association with metabolic and hormonal balance. Berberine is commonly studied for its potential role in supporting glucose metabolism and insulin sensitivity, while Korean red ginseng is often linked to improved vitality, energy support, and stress resilience.

Note: Research generally supports individual ingredients rather than the finished Citrus Burn formulation. Individual results may vary.

Potential Benefits Commonly Associated With CitrusBurn

Citrus Burn is promoted as a daily metabolism support supplement designed to work in harmony with the body’s natural fat-burning and energy-production processes.

While individual outcomes can vary, citrus-based metabolic supplements like CitrusBurn are commonly associated with several potential benefits.

CitrusBurn is designed to support natural thermogenic activity, helping the body convert stored calories into usable energy more efficiently. Certain ingredients in the formula may also support appetite awareness, which can help reduce unnecessary snacking and manage cravings throughout the day.

Unlike stimulant-heavy products, Citrus Burn aims to promote clean, sustained energy, supporting steady energy levels, reduced crashes, and improved daily focus. Additionally, metabolic cofactors such as berberine and vinegar extracts are often associated with supporting balanced blood sugar levels and more consistent energy output.

CitrusBurn is intended to complement healthy nutrition and regular physical activity, making it suitable for individuals pursuing lifestyle-based weight and metabolic goals rather than quick-fix solutions.

CitrusBurn Pricing: Package Options and Cost Breakdown

CitrusBurn pricing is structured around multi-bottle packages designed to support consistent, long-term metabolic use. This tiered pricing approach is common among metabolism support supplements and allows customers to choose a package based on their usage goals and budget.

CitrusBurn Available Packages and Prices

• 6-Bottle Package (180-Day Supply)
  • Approximate cost: $49 per bottle
  • Lowest price per unit
  • Frequently includes free shipping
  • Most commonly selected option for long-term metabolic support
• 3-Bottle Package (90-Day Supply)
  • Approximate cost: $69 per bottle
  • Mid-range pricing option
  • Popular choice for first-time CitrusBurn users
• 2-Bottle Package (60-Day Supply)
  • Approximate cost: $79 per bottle
  • Entry-level package
  • Suitable for short-term evaluation before committing to a larger supply

Pricing and promotional discounts may vary depending on availability, seasonal offers, and demand. Multi-bottle packages are generally recommended for individuals seeking ongoing metabolism support.

Where to Buy CitrusBurn Safely

CitrusBurn is primarily available for purchase through the official CitrusBurn website. Buying directly from the source helps ensure product authenticity, proper storage conditions, and access to customer guarantees.

Recommended Purchasing Guidelines

To avoid counterfeit or expired products, consumers are typically encouraged to:

• Buy CitrusBurn only from the official website
• Avoid third-party marketplaces or unauthorized sellers
• Review current promotions, refund terms, and shipping details before ordering

CitrusBurn Shipping and Money-Back Guarantee

Most official Citrus Burn orders include secure checkout, tracked shipping, and access to a money-back guarantee that may extend up to 180 days. Purchasing directly from the official source helps ensure eligibility for customer support, refund policies, and verified product quality.

Below is a more SEO-optimized version of your content.
I’ve strengthened keyword targeting, heading hierarchy, semantic depth, and search intent alignment while keeping the meaning, tone, and compliance intact.

Primary SEO focus keywords integrated naturally:

• Citrus-based metabolism supplements
• Citrus-derived nutrients
• Orange peel trick
• Thermogenesis support
• Metabolic efficiency
• Natural thermogenic supplements
• CitrusBurn metabolism support

Understanding the Rising Interest in Citrus-Based Metabolism Supplements

Citrus-based metabolism supplements have gained significant attention in recent years as consumers seek natural, plant-derived options to support metabolic health, energy balance, and thermogenic activity. This growing interest reflects both advances in ingredient research and shifting consumer preferences toward sustainable, stimulant-free metabolic support.

Why Citrus-Derived Nutrients Are Gaining Attention in Metabolic Health

Over the past decade, citrus-derived nutrients have become an increasingly studied focus within nutritional science and the dietary supplement industry. Citrus fruits, and especially their peels, contain naturally occurring bioactive compounds such as flavonoids, alkaloids, and polyphenols. These compounds are being examined for their roles in metabolic signaling, antioxidant defense, and cellular energy regulation.

Citrus peels, in particular, have attracted attention because they contain higher concentrations of certain compounds that are not present in the same amounts within the fruit pulp. Research has explored these compounds in relation to fat oxidation, glucose metabolism, and appetite-related signaling pathways. This expanding body of ingredient-level research has contributed to online discussions commonly referred to as the “orange peel trick” or “orange peel hack” for metabolism and weight management.

While these phrases are widely used in consumer-focused content, nutrition researchers and supplement formulators emphasize that citrus-derived compounds should be evaluated within a broader metabolic framework. No single ingredient is viewed as a standalone solution, and metabolic health is influenced by multiple interconnected biological processes.

Growing Consumer Demand for Natural Thermogenic Support

Global demand for metabolism support supplements has accelerated, particularly among adults over the age of 35 who experience natural metabolic changes related to hormonal shifts, reduced thermogenesis, and altered energy expenditure. As awareness grows, many consumers are actively seeking alternatives to traditional stimulant-heavy fat burners, which are often associated with jitteriness, sleep disruption, and inconsistent energy levels.

Citrus-based thermogenic supplements have emerged as a category positioned between functional nutrition and conventional fat-burning products. These formulas typically emphasize plant-based ingredients, moderate metabolic activation, and compatibility with daily routines. CitrusBurn aligns with this positioning by combining citrus peel extracts with other botanicals commonly associated with metabolic support and energy balance.

Industry analysts note that the appeal of citrus-based metabolism supplements is driven not only by ingredient research but also by consumer preferences for clean-label formulations, non-habit-forming products, and solutions that support gradual, sustainable metabolic outcomes rather than rapid or extreme weight fluctuations.

The Science Behind Thermogenesis and Metabolic Efficiency

What Is Thermogenesis and Why It Declines With Age

Thermogenesis refers to the body’s natural process of producing heat through calorie expenditure. This process plays a key role in regulating body temperature, supporting digestion, and determining how efficiently the body converts stored energy into usable fuel. A significant portion of daily calorie burn occurs through thermogenic activity rather than physical movement alone.

Scientific research suggests that thermogenic efficiency tends to decline with age, particularly after the mid-30s. Factors contributing to this decline may include reduced mitochondrial function, hormonal changes, shifts in insulin sensitivity, and alterations in nervous system signaling. As thermogenesis becomes less efficient, maintaining body composition can become more challenging even when diet and activity habits remain unchanged.

These age-related changes have prompted researchers to examine dietary compounds and botanical extracts that may help support thermogenic pathways without overstimulating the nervous system.

Thermogenic Resistance and Its Impact on Weight Management

Thermogenic resistance is a term increasingly used to describe reduced responsiveness to signals that initiate fat oxidation and calorie burning. In practical terms, this means the body may store energy more easily while becoming less efficient at accessing stored fat for fuel.

Although research in this area is ongoing, metabolic experts generally agree that supporting thermogenesis requires a multifactor approach that includes nutrition, physical activity, sleep quality, and hormonal balance. Supplements such as CitrusBurn are positioned as supportive tools within this broader lifestyle framework rather than as primary drivers of metabolic change.

By focusing on citrus-derived compounds associated with metabolic signaling, Citrus Burn is marketed as a formula intended to complement healthy habits rather than replace them.

Metabolism, Energy Production, and Fat Oxidation Explained

Metabolism refers to the complex network of biochemical processes responsible for converting food into energy, maintaining cellular structure, and supporting overall physiological balance. Fat oxidation is one component of metabolism and involves breaking down stored lipids into energy molecules that the body can use.

Certain plant-based compounds have been studied for their influence on enzymes and receptors involved in these processes. Citrus-derived flavonoids, alkaloids, and polyphenols have been examined for their potential roles in energy expenditure and metabolic signaling, particularly when used alongside other supportive nutrients.

CitrusBurn’s formulation reflects this ingredient synergy approach, emphasizing balanced metabolic support rather than isolated stimulation. This strategy aligns with evolving scientific perspectives that favor sustainable metabolic activation over aggressive, short-term calorie-burning methods.

Key Citrus-Derived Compounds and Their Roles in Metabolic Support

Citrus-derived compounds have become a major focus in the development of citrus-based metabolism supplements due to their association with thermogenesis, energy balance, and metabolic efficiency. These naturally occurring plant compounds are commonly studied for their ability to support calorie utilization without overstimulating the nervous system.

Citrus Peel Compounds and Thermogenic Signaling

Citrus peels contain naturally occurring alkaloids and flavonoids that have been studied for their interaction with adrenergic receptors involved in energy expenditure. These interactions may help support mild thermogenic activity, which can contribute to increased calorie burning when combined with regular physical activity and balanced nutrition.

Unlike high-dose synthetic stimulants, citrus-derived thermogenic compounds are often described as supporting metabolic alertness rather than triggering sharp spikes in nervous system stimulation. This more moderate effect profile has contributed to their widespread use in daily metabolism support supplements such as CitrusBurn.

Citrus Flavonoids and Antioxidant Support for Metabolic Health

Flavonoids found in citrus peels, including hesperidin and related polyphenols, are widely recognized for their antioxidant properties. Antioxidants play an important role in protecting cells from oxidative stress, a process closely associated with metabolic aging and reduced cellular efficiency.

By supporting antioxidant defenses, citrus-derived flavonoids may help maintain healthier metabolic function over time. This benefit is frequently discussed in the context of long-term metabolic wellness rather than short-term or rapid weight loss, aligning with the positioning of citrus-based metabolism supplements.

Energy Balance, Appetite Awareness, and Metabolic Regulation

Beyond thermogenic pathways, certain citrus-derived compounds have been examined for their potential influence on appetite signaling and blood sugar regulation. Stable energy levels and reduced fluctuations in hunger may help support healthier eating behaviors and more consistent dietary patterns.

CitrusBurn’s formulation approach emphasizes metabolic awareness rather than artificial appetite suppression. This positioning aligns with growing consumer demand for natural metabolism support solutions that work alongside lifestyle habits instead of overriding normal physiological signals.

Citrus Burn Ingredient Framework: A Research-Based Perspective

Ingredient-Level Research vs Finished Product Claims

Within the dietary supplement industry, scientific evidence is most commonly available at the individual ingredient level rather than for finished formulations. CitrusBurn follows this standard approach by incorporating botanicals and micronutrients that have been individually studied for roles related to metabolism, thermogenesis, energy regulation, and appetite awareness.

While CitrusBurn as a completed supplement has not been publicly linked to large-scale independent clinical trials, its formulation reflects ingredients that appear frequently in metabolic and thermogenic research literature. Understanding this distinction is essential for consumers evaluating metabolism support supplements responsibly.

Seville Orange Peel (Citrus aurantium) and Metabolic Support

Seville orange peel extract is one of the most widely discussed citrus-derived ingredients in metabolism-focused supplements. Research on Citrus aurantium has examined compounds such as p-synephrine, which may support metabolic rate through interactions with adrenergic receptor pathways involved in fat oxidation and energy expenditure.

Unlike ephedrine-based stimulants, p-synephrine is often described in scientific literature as having a milder cardiovascular impact when used responsibly and at appropriate doses. This characteristic has contributed to its inclusion in citrus-based thermogenic supplements designed for regular use.

Individual responses may vary depending on health status, stimulant sensitivity, and total caffeine intake from other sources.

Green Tea Extract and Fat Oxidation Support

Green tea extract is among the most extensively researched botanicals in metabolic health studies. Its catechins, particularly epigallocatechin gallate (EGCG), have been examined for their potential role in supporting fat oxidation and increasing energy expenditure.

Green tea extract is commonly included in metabolism supplements because it offers both antioxidant support and mild thermogenic activity. When combined with citrus-derived compounds, it may help support calorie utilization during physical activity and daily movement.

CitrusBurn includes green tea–derived compounds as part of a broader metabolic support framework rather than positioning them as a standalone fat-burning solution.

Botanical Cofactors and Cellular Energy Regulation

In addition to citrus peel and green tea extracts, CitrusBurn formulations typically include botanical cofactors associated with energy metabolism and nutrient utilization. These ingredients are selected to complement thermogenic compounds rather than amplify stimulant effects.

Such cofactors may help support mitochondrial function, carbohydrate metabolism, and cellular energy production. This formulation philosophy reflects modern supplement trends that prioritize metabolic efficiency, balance, and sustainability over aggressive stimulation.

How CitrusBurn Differs From Traditional Fat Burners

Citrus Burn is often compared to traditional fat burners due to its citrus-based formulation and non-stimulant-forward positioning. Understanding how CitrusBurn differs from conventional fat-burning supplements can help consumers evaluate whether citrus-based metabolism support aligns with their goals and tolerance preferences.

Stimulant-Heavy Fat Burners vs Citrus-Based Metabolism Support

Many traditional fat burners rely on high doses of caffeine, synthetic stimulants, or aggressive thermogenic compounds designed to rapidly increase heart rate and central nervous system activity. While some consumers seek this immediate surge of energy, others report side effects such as jitteriness, energy crashes, sleep disruption, or poor long-term tolerance.

CitrusBurn is positioned as a citrus-based metabolism support supplement that emphasizes smoother energy and daily usability rather than intense stimulation. This contrast is frequently highlighted in comparisons between citrus-derived metabolism supplements and conventional stimulant-heavy fat burners.

“Clean Energy” Support vs Jitter-Driven Stimulation

A commonly discussed concept in CitrusBurn reviews and consumer feedback is the idea of “clean energy.” This term is often used to describe energy support that feels steady and manageable, without the nervousness, anxiety, or abrupt energy drops associated with high-stimulant products.

Citrus-derived compounds and botanical extracts are frequently framed as supporting metabolic alertness and energy balance without overwhelming the nervous system. While individual responses vary, this positioning reflects broader wellness trends favoring sustainable energy over short-lived stimulation.

Appetite Awareness Compared to Appetite Suppression

Traditional fat burners often aim to suppress appetite through aggressive mechanisms, which may not support long-term dietary adherence. In contrast, citrus-based metabolism supplements are commonly marketed as supporting appetite awareness and natural satiety signals.

CitrusBurn’s formulation messaging aligns with this approach by emphasizing metabolic support alongside mindful eating habits, rather than presenting the supplement as a substitute for proper nutrition or a tool for extreme calorie restriction.

Safety, Tolerance, and Responsible Supplement Use

Who Typically Uses Citrus-Based Metabolism Supplements

CitrusBurn is generally marketed toward adults seeking metabolic support, particularly individuals who feel their metabolism has slowed with age. This includes people who maintain consistent diet and exercise routines but are looking for additional nutritional support to complement their lifestyle.

As with all dietary supplements, CitrusBurn is not intended to diagnose, treat, cure, or prevent disease. Individuals with medical conditions, stimulant sensitivities, or those taking prescription medications are encouraged to consult a healthcare professional before use.

Potential Interactions and Sensitivity Considerations

Some citrus-derived compounds may interact with medications, especially those processed through liver enzyme pathways. Individuals sensitive to stimulants should also consider their total daily intake of caffeine and related compounds from all dietary sources.

Responsible use includes following label directions, avoiding excessive stacking with other stimulant-containing supplements, and monitoring individual response over time.

Manufacturing Standards and Product Quality Considerations

CitrusBurn products are typically manufactured in facilities that comply with standard dietary supplement regulations, including Good Manufacturing Practices (GMP). These standards address ingredient sourcing, purity, and manufacturing consistency.

Although regulatory compliance does not equate to clinical effectiveness, it provides a baseline level of quality assurance for consumers navigating the metabolism supplement market.

Growing Consumer Demand for Citrus-Based Metabolism Supplements

Why Citrus-Derived Formulas Are Increasingly Popular

Over the past decade, consumer preferences in the supplement industry have shifted toward plant-based, clean-label, and naturally sourced products. Citrus-based metabolism supplements like CitrusBurn have emerged within this trend, benefiting from long-standing associations between citrus ingredients and wellness, digestion, and vitality.

Citrus flavors and botanical extracts are often perceived as fresher and more approachable than synthetic stimulant blends. This perception plays a meaningful role in consumer adoption, especially among individuals seeking metabolism support without aggressive stimulation.

Metabolism Support Demand After Age 35

Age-related metabolic slowdown is one of the most common reasons consumers explore metabolism supplements. Research and consumer surveys consistently show that adults over 35 often experience increased difficulty managing energy levels, appetite regulation, and body composition, even when diet and exercise habits remain consistent.

CitrusBurn and similar citrus-based metabolism supplements are frequently positioned toward this demographic, offering a formulation narrative focused on supporting natural metabolic pathways rather than promoting rapid or extreme weight loss.

This audience often prioritizes sustainable energy, digestive comfort, ingredient tolerance, and products that integrate easily into daily routines.

Clean-Label Preferences and Ingredient Transparency

Ingredient transparency has become a major decision factor for supplement buyers. Many consumers now review ingredient lists, sourcing information, and manufacturing practices before making a purchase.

CitrusBurn’s emphasis on recognizable botanical ingredients aligns with this clean-label trend. Citrus-derived compounds, green tea extracts, and botanical cofactors are generally more familiar to consumers than synthetic stimulants, contributing to higher perceived trust and confidence.

Conclusion: Should You Buy CitrusBurn?

Citrus Burn operates within the growing natural metabolism and weight-management supplement category, leveraging consumer interest in citrus-derived botanicals and functional nutrition.

While CitrusBurn is not a medical treatment or guaranteed solution, its formulation reflects current market preferences that favor plant-based ingredients, metabolic pathway support, and clean-label positioning.

As consumer awareness continues to evolve, citrus-based metabolism supplements like CitrusBurn are likely to remain central to discussions around metabolic health, lifestyle wellness, and nutraceutical innovation.

Final Note on Citrus Burn

Like all dietary supplements, CitrusBurn is best viewed as part of a broader wellness strategy that includes balanced nutrition, regular physical activity, and informed health decisions. For official product details, guarantees, and current availability, consumers are encouraged to visit the official CitrusBurn website.

Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. CitrusBurn is a dietary supplement and is not designed to diagnose, treat, cure, or prevent any disease. Individual results may vary depending on health status, lifestyle, and personal factors. Always consult a qualified healthcare professional before starting any new supplement, especially if you are pregnant, nursing, have a medical condition, or are taking prescription medications. Do not exceed recommended dosages. This content should not replace professional medical guidance, nutritional counseling, or personalized health advice from a licensed practitioner.

Project name: CitrusBurn

• Phone
  + 1 (800) 390-6035 (24/7)
• Email support@citrusburn.com.
• Advertise with us: Info@allprsolution.com

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock




Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $350.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock. All of the shares to be sold in the proposed offering are to be sold by Crinetics. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Crinetics intends to use the net proceeds from the proposed offering, together with its cash, cash equivalents and investment securities, to fund its commercial activities in connection with the launch of PALSONIFY™, research and development of its product candidates, other research programs and other general corporate purposes, which may include, among other things, capital expenditures or working capital. Crinetics may also use a portion of the remaining net proceeds, together with its existing cash, cash equivalents and investment securities, to in-license, acquire, or invest in complementary businesses, technologies, products or assets; however, it has no current commitments or obligations to do so.

Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler and Cantor are acting as joint bookrunning managers for the proposed offering.

The securities described above are being offered by Crinetics pursuant to a shelf registration statement that became automatically effective upon its filing with the Securities and Exchange Commission (“SEC”). The proposed offering may be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.

Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements relating to the offering, including the structure, timing, size and completion of the offering and the anticipated use of proceeds therefrom, and the grant of the option to purchase additional shares. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “upcoming” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, the risks and uncertainties inherent in Crinetics’ business, including the risks and uncertainties described in the company’s periodic filings with the SEC. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended September 30, 2025, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contacts

Investors: 
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075 

Plum Tree Launches 2026 with Expanded Access to Mental Health Care for Children and Adolescents




Plum Tree Launches 2026 with Expanded Access to Mental Health Care for Children and Adolescents

ST. CHARLES, Ill., Jan. 05, 2026 (GLOBE NEWSWIRE) — As families enter the new year, Plum Tree Psychology, a child and adolescent behavioral health practice serving Kane County and surrounding communities, is expanding access to care in response to the growing mental health needs of children, teens, and families.

January is historically one of the busiest times of year for pediatric mental health services, as academic pressure, anxiety, mood concerns, and learning challenges often surface or intensify following the holiday break. In anticipation of this annual surge, Plum Tree Psychology has increased appointment availability and service capacity to help families access timely support when it matters most.

“Families are telling us they want help sooner, not months down the road,” said David Savoia, Practice Manager at Plum Tree. “As we begin 2026, our focus is on reducing barriers to care and ensuring children and adolescents receive the support they need as early as possible.”

Expanding Access While Preserving Personalized Care

Plum Tree’s 2026 expansion includes a new office build-out, increased clinical availability and continued investment in comprehensive services for children and adolescents, including therapy, psychological and neuropsychological evaluations, and collaborative care with schools and pediatric providers.

While the practice continues to grow, leadership emphasizes that its core mission remains unchanged: providing individualized, multidisciplinary care in a supportive and welcoming environment.

“Growth only matters if it improves the experience for families,” Savoia added. “Our goal is to expand responsibly so children feel known, parents feel supported, and care never feels rushed or impersonal.”

Meeting a Rising Community Need

Local educators and healthcare providers report increasing emotional, behavioral, and learning-related concerns among students, particularly during the winter months. By expanding access at the start of the year, Plum Tree aims to help families address challenges before they escalate and to support children in both their emotional well-being and academic success.

Plum Tree also plans to continue strengthening partnerships with schools, pediatric practices, and community organizations throughout 2026 to promote early identification and coordinated care.

About Plum Tree

Plum Tree Psychology is a child and adolescent behavioral health practice dedicated to supporting the emotional, developmental, and psychological well-being of children, teens, and families. Serving Kane County and surrounding communities, Plum Tree provides evidence-based therapy, psychological and neuropsychological evaluations, and collaborative care designed to meet families where they are.

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/0294f40f-1343-44a6-9cb3-205b7ad0ceb3

Contact information: hello@theplumtree.net / https://www.theplumtree.net/

Idorsia’s daridorexant in women during menopausal transition age with insomnia




Idorsia’s daridorexant in women during menopausal transition age with insomnia

• New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition age
• Brigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symptoms

Allschwil, Switzerland – January 5, 2026
Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition age: Insights from a randomized controlled trial” in Maturitas, a prestigious international journal of midlife health and beyond. This new analysis of the efficacy and safety of daridorexant in women aged 47–55 years with insomnia disorder – a population representative of the menopausal transition – is based on data from the Phase 3 randomized controlled trial (NCT03545191) published in Lancet Neurology and provides important insights into the management of insomnia during in midlife women.

One of the most prevalent and burdensome yet under-researched symptoms reported by women in the menopausal transition is sleep disturbance^1,2. Multiple factors, including hormonal changes, vasomotor symptoms (e.g. hot flushes, night sweats), psychological changes (e.g. mood symptoms, depression), development of other sleep disorders (e.g. restless legs syndrome, obstructive sleep apnea), and social demands (e.g. caregiving), may contribute, either triggering the onset of or exacerbating preexisting sleep disturbances³. Sleep disturbances can have a significant impact on physical and mental health, quality of life, and productivity⁴.

Key findings
Daridorexant 50 mg improved both sleep and daytime functioning compared to placebo.
Change from baseline at Month 3:

• Wake after sleep onset (WASO) was improved by ~43 minutes.
• Latency to persistent sleep (LPS) was improved by ~34 minutes.
• Self-reported total sleep time was improved by ~75 minutes.
• Daytime functioning and sleep quality scores were improved.

Furthermore, the incidence of somnolence and fatigue was low and comparable to placebo, and no increase in next-morning sleepiness was observed compared to placebo.

Dr Zoe Schaedel, BMedSci, BMBS, MRCGP, DRCOG, DFSRH, PGCertMedEd, General Practitioner, British Menopause Society (BMS) Menopause Specialist and co-author of the manuscript, commented: “Insomnia disorder affects approximately one in four women during the menopausal transition, yet is often underdiagnosed and certainly undertreated. This analysis shows that daridorexant 50 mg offered meaningful improvements in sleep and daytime functioning without compromising safety. It is essential that clinicians consider the diagnosis of insomnia disorder when sleep disturbances arise during the menopause transition rather than considering it merely secondary to menopausal symptoms, allowing access to evidence-based treatments.”

New Brigham and Women’s Hospital study
Principal investigators, Dr Bertisch and Dr Redline, from the Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, have selected daridorexant, Idorsia’s dual orexin receptor antagonist (DORA), to be included in a study, CELESTE, focused on menopause-related insomnia. The study will compare the effectiveness and safety of different approaches to treat menopause-related insomnia, including daridorexant as the only pharmacotherapy approved for the treatment of insomnia. Results will help clinicians and their patients when considering ways to treat menopause-related insomnia.

Delivering on the company’s commitment to advance the science of sleep and insomnia, Idorsia will be providing daridorexant at no cost, to support this ground-breaking study.

Antonio Olivieri, MD, Chief Medical Officer & Head of Global Medical Affairs at Idorsia commented: “We are excited for daridorexant to be included in this important study, as insomnia is associated with numerous serious health conditions, and is particularly common in women dealing with menopause. Daridorexant works differently from other insomnia medications by decreasing overactive wake signaling, which is a key cause of insomnia. We look forward to seeing the results and continuing to advance the science of insomnia.”

About the CELESTE study NCT07136415
Funded by the Patient-Centered Outcomes Research Institute (PCORI), the CELESTE study will include around 900 peri- and post-menopausal women with insomnia. Participants will receive treatment for 12 months and insomnia symptoms will be measured using surveys at the start of the study and again three, six and 12 months later. Treatments, including daridorexant, which is approved by the FDA for adults with insomnia, will be monitored to see if they work differently based on factors such the severity of hot flashes, presence of sleep apnea, and menopause stage. The study will be randomized with daridorexant being one of the three-arm study and is expected to be conducted over a 60-month period.

Global availability of daridorexant
Daridorexant is marketed as QUVIVIQ™ by Idorsia in the US, Canada, and multiple European countries, and is available in Japan, Hong Kong, and China through strategic partnerships.

The daridorexant Phase 3 registration program⁵
The global registration program demonstrated that 25mg and 50mg doses of daridorexant significantly improved sleep onset, sleep maintenance and self-reported total sleep time at months 1 and 3 compared to placebo. A major focus of the trials was to evaluate the impact of daridorexant on daytime functioning in patients with insomnia, as assessed by the IDSIQ. The sleepiness domain score of the IDSIQ was evaluated as a key secondary endpoint in both pivotal studies, and comparisons to placebo included control for multiplicity. Daridorexant 50 mg demonstrated a highly significant improvement in daytime functioning, as measured by the sleepiness domain at month 1 and month 3.

For the US:
Important Safety Information

Do not take QUVIVIQ if you fall asleep often at unexpected times (narcolepsy) or if you are allergic to QUVIVIQ or any of its ingredients.

QUVIVIQ may cause serious side effects, including:

• Decreased awareness and alertness. The morning after you take QUVIVIQ, your ability to drive safely and think clearly may be decreased. You may also have sleepiness during the day. Sleepiness may increase your risk of falls.
  • Do not take more QUVIVIQ than prescribed.
  • Do not take QUVIVIQ unless you are able to stay in bed for at least 7 hours before you must be active again.
  • Take QUVIVIQ at night within 30 minutes before going to bed.

QUVIVIQ is a federally controlled substance because it can be abused or lead to dependence.

Before taking QUVIVIQ, tell your healthcare provider about all of your medical conditions, including if you:

• have a history of depression, mental illness, or suicidal thoughts or actions; drug or alcohol abuse or addiction; a sudden onset of muscle weakness (cataplexy); daytime sleepiness
• have lung or breathing problems, including sleep apnea
• have liver problems
• are pregnant or plan to become pregnant
• are breastfeeding or plan to breastfeed

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

• Taking QUVIVIQ with certain medicines can cause serious side effects. QUVIVIQ may affect the way other medicines work and other medicines may affect the way QUVIVIQ works.
• Do not take QUVIVIQ with other medicines that can make you sleepy unless instructed by your healthcare provider.

What should I avoid while taking QUVIVIQ?

• Do not drink alcohol while taking QUVIVIQ. It can increase the effects of alcohol, which can be dangerous.  
• Do not drive, operate heavy machinery, do anything dangerous, or do other activities that require clear thinking if you do not feel fully awake, or you have taken QUVIVIQ and have less than a full night of sleep (at least 7 hours), or if you have taken more QUVIVIQ than prescribed.

QUVIVIQ may cause other serious side effects, including:

• Worsening depression and suicidal thoughts. Call your healthcare provider right away if you have any worsening depression or thoughts of suicide or dying.
• Temporary inability to move or talk (sleep paralysis) for up to several minutes, or hallucinations while you are going to sleep or waking up.
• Temporary weakness in your legs that can happen during the day or at night
• Complex sleep behaviors such as sleepwalking, sleep-driving, preparing and eating food, making phone calls, having sex or doing other activities while not fully awake that you may not remember the next morning. Stop taking QUVIVIQ and call your healthcare provider right away if you experience a complex sleep behavior.

The most common side effects of QUVIVIQ are headache and sleepiness or tiredness.

These are not the only side effects of QUVIVIQ. Call your doctor for advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Notes to the editor

About insomnia
Insomnia is defined as a combination of dissatisfaction with sleep and a significant negative impact on daytime functioning. Dissatisfaction with sleep refers to the difficulty to initiate and/or maintain sleep on at least three nights per week for at least three months, despite adequate opportunity to sleep.

Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia.

Insomnia as a disorder is quite different from a brief period of poor sleep, and it can take its toll on both physical and mental health. It is a persistent condition with a negative impact on daytime functioning. Idorsia’s research has shown that poor-quality sleep can affect many aspects of daily life, including the ability to concentrate, mood, and energy levels.

The goals of managing insomnia are to improve sleep quality and quantity, as well as daytime functioning. Current recommended treatment of insomnia includes sleep hygiene recommendations, cognitive behavioral therapy and pharmacotherapy.

About Dr Zoe Schaedel
Dr Zoe Schaedel, of Myla Health, is an experienced Menopause Specialist. She specialises in women’s health, menopause care, sexual health and contraception. She is an accredited specialist with the British Menopause Society (BMS) and is a member of the BMS Medical Advisory Council.

Dr Schaedel contributes to a number of national committees including the NHS England Menopause Improvement Programme and she has delivered talks and masterclasses nationally and to organisations on menopause and on the interplay between menopause, mental health and sleep. She has published articles on menopause in The Lancet and Post Reproductive Health. Dr Schaedel is a trainer for the British Menopause Society and loves to support clinicians who want to further their knowledge on women’s health. Dr Schaedel serves as a consultant to Idorsia.

References

1. El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. Oct 2019;26(10):1213-1227. doi:10.1097/gme.0000000000001424
2. Schaedel Z, Holloway D, Bruce D, Rymer J. Management of sleep disorders in the menopausal transition. Post Reproductive Health. 2021;27(4):209-214. doi:10.1177/20533691211039151
3. Tobias L, Thapa S, Won CHJ. Impact of Sex on Sleep Disorders Across the Lifespan. Clinics in Chest Medicine. 2021/09/01/ 2021;42(3):427-442. doi:https://doi.org/10.1016/j.ccm.2021.04.005
4. Bolge SC, Joish VN, Balkrishnan R, Kannan H, Drake CL. Burden of chronic sleep maintenance insomnia characterized by nighttime awakenings. Popul Health Manag. Feb 2010;13(1):15-20. doi:10.1089/pop.2009.0028
5. Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022 Feb;21(2):125-139. doi: 10.1016/S1474-4422(21)00436-1.

About Idorsia
The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “intend”, “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

• Press Release PDF

Zealand Pharma to present at the J.P. Morgan Healthcare Conference




Zealand Pharma to present at the J.P. Morgan Healthcare Conference

Press release – No. 1 / 2026

Zealand Pharma to present at the J.P. Morgan Healthcare Conference

Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44^th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California.

Adam Steensberg, President and Chief Executive Officer, will take part in a presentation and fireside chat on Wednesday January 14 at 1:30pm PST / 10:30pm CET. A live audio webcast will be available at: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317741-zealand-pharma/webcast?gpu_only=true&kiosk=true.
A replay of the webcast will be available at https://www.zealandpharma.com/events/.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.  

Contacts
Adam Lange (Investors)
Vice President, Investor Relations
Zealand Pharma
Email: alange@zealandpharma.com

Neshat Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com

Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Zealand Pharma
RJamesOwens@zealandpharma.com

Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783